Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.

The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.

Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.